Cargando…
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
BACKGROUND: Bone and soft tissue sarcomas (BSTS) are rare malignant tumors. Recently, the combination of gemcitabine and docetaxel (GD) was shown to have activity as second-line setting in BSTS. However, the efficacy as first-line and adjuvant settings and precise profiles of adverse events in Japan...
Autores principales: | Tanaka, Kazuhiro, Joyama, Susumu, Chuman, Hirokazu, Hiraga, Hiroaki, Morioka, Hideo, Yoshikawa, Hideki, Hosaka, Masami, Takahashi, Mitsuru, Kubo, Tadahiko, Hatano, Hiroshi, Kaya, Mitsunori, Toguchida, Junya, Nishida, Yoshihiro, Nagano, Akihito, Tsumura, Hiroshi, Iwamoto, Yukihide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146834/ https://www.ncbi.nlm.nih.gov/pubmed/27931230 http://dx.doi.org/10.1186/s12957-016-1059-2 |
Ejemplares similares
-
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
por: Tanaka, Kazuhiro, et al.
Publicado: (2022) -
Prospective comparison of various radiological response criteria and pathological response to preoperative chemotherapy and survival in operable high-grade soft tissue sarcomas in the Japan Clinical Oncology Group study JCOG0304
por: Tanaka, Kazuhiro, et al.
Publicado: (2018) -
Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study
por: Urakawa, Hiroshi, et al.
Publicado: (2018) -
Docetaxel/gemcitabine: Various toxicities: 4 case reports
Publicado: (2021) -
SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)